Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells.
A549 Cells
Aminacrine
/ chemistry
Apoptosis
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ pathology
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
Colorectal Neoplasms
/ pathology
Cytoprotection
/ drug effects
DNA
/ metabolism
Drug Resistance, Neoplasm
/ drug effects
G1 Phase Cell Cycle Checkpoints
/ drug effects
HT29 Cells
Histones
/ metabolism
Humans
Hyaluronoglucosaminidase
/ metabolism
Inhibitory Concentration 50
Iodobenzoates
/ pharmacology
Lung Neoplasms
/ pathology
Mutagens
/ toxicity
Oxidative Stress
/ drug effects
Poly(ADP-ribose) Polymerases
/ metabolism
Tumor Stem Cell Assay
A549
Apoptosis
Cell cycle arrest
Cytotoxicity
HT-29
PARP-1
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
20
01
2019
accepted:
21
06
2019
pubmed:
18
7
2019
medline:
14
1
2020
entrez:
18
7
2019
Statut:
ppublish
Résumé
A series of nine tetrahydroacridine derivatives with iodobenzoic moiety were synthesized and evaluated for their cytotoxic activity against cancer cell lines-A549 (human lung adenocarcinoma), HT-29 (human colorectal adenocarcinoma) and somatic cell line-EA.hy926 (human umbilical vein cell line). All compounds displayed high cytotoxicity activity against A549 (IC
Identifiants
pubmed: 31313023
doi: 10.1007/s11010-019-03576-x
pii: 10.1007/s11010-019-03576-x
pmc: PMC6745035
doi:
Substances chimiques
H2AX protein, human
0
Histones
0
Iodobenzoates
0
Mutagens
0
Aminacrine
78OY3Z0P7Z
DNA
9007-49-2
Poly(ADP-ribose) Polymerases
EC 2.4.2.30
Hyaluronoglucosaminidase
EC 3.2.1.35
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-150Subventions
Organisme : Uniwersytet Medyczny w Lodzi
ID : 503/3-015-01/503-31-002
Organisme : Uniwersytet Medyczny w Lodzi
ID : 502-02/3-015-01/502-34-091
Références
Cancer Invest. 2013 Nov;31(9):582-99
pubmed: 24164298
J Am Coll Nutr. 2001 Oct;20(5 Suppl):464S-472S; discussion 473S-475S
pubmed: 11603657
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31(1):45-66
pubmed: 23534394
Nutr Cancer. 2000;37(1):1-18
pubmed: 10965514
Annu Rev Med. 2002;53:615-27
pubmed: 11818492
NeuroRx. 2005 Oct;2(4):541-53
pubmed: 16489364
Oncol Lett. 2014 May;7(5):1556-1562
pubmed: 24765175
Cancer Res. 1998 Aug 15;58(16):3495-8
pubmed: 9721847
Bioorg Med Chem Lett. 2016 Feb 1;26(3):1073-1079
pubmed: 26739776
J Cell Sci. 2001 Oct;114(Pt 20):3771-8
pubmed: 11707529
EXCLI J. 2016 Feb 12;15:113-8
pubmed: 27047321
Biochem Pharmacol. 2007 Jun 15;73(12):1863-72
pubmed: 17391647
Toxicol Sci. 2004 May;79(1):137-46
pubmed: 14976342
Chem Res Toxicol. 2011 Sep 19;24(9):1420-56
pubmed: 21790149
Cancer Chemother Pharmacol. 1995;35(5):432-6
pubmed: 7850926
Eur J Med Chem. 2011 Jun;46(6):2224-35
pubmed: 21420206
Br J Clin Pharmacol. 2011 Jul;72(1):162-3
pubmed: 21204909
Eur J Cell Biol. 2001 Jun;80(6):442-9
pubmed: 11484935
J Biol Chem. 1997 Mar 14;272(11):7223-8
pubmed: 9054418
J Am Coll Nutr. 2002 Oct;21(5):416-21
pubmed: 12356783
Free Radic Biol Med. 2013 Dec;65:305-316
pubmed: 23837948
J Pharmacol Exp Ther. 2003 Jun;305(3):932-42
pubmed: 12649303
ACS Chem Biol. 2013 Jan 18;8(1):82-95
pubmed: 23259582
Evid Based Complement Alternat Med. 2016;2016:8090841
pubmed: 27051453
Blood. 1999 Dec 15;94(12):4143-55
pubmed: 10590059
ACS Chem Neurosci. 2014 Sep 17;5(9):770-5
pubmed: 25008046
Phytomedicine. 2019 Mar 15;56:156-164
pubmed: 30668336
Nature. 1994 Sep 22;371(6495):346-7
pubmed: 8090205
J Nucleic Acids. 2010 Aug 03;2010:
pubmed: 20811597
Eur J Pharmacol. 2009 Apr 1;607(1-3):47-53
pubmed: 19233161
J Appl Toxicol. 2017 Oct;37(10):1132-1139
pubmed: 28370171
J Pharm Pharm Sci. 2013;16(4):622-47
pubmed: 24210068
J Pharm Sci. 2007 Sep;96(9):2181-96
pubmed: 17593552
Cancer Res. 1991 Feb 15;51(4):1078-85
pubmed: 1847655
J Fluoresc. 2015 Jul;25(4):941-59
pubmed: 26006100
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:1399-1410
pubmed: 28415431
Molecules. 2013 Mar 04;18(3):2878-94
pubmed: 23459299
J Antimicrob Chemother. 2001 Jan;47(1):1-13
pubmed: 11152426
Int J Mol Sci. 2012;13(8):10067-90
pubmed: 22949848
Cell Commun Signal. 2010 Dec 22;8:31
pubmed: 21176168
Carcinogenesis. 2015 Dec;36(12):1484-93
pubmed: 26442524
Molecules. 2017 Mar 06;22(3):
pubmed: 28272321
Int J Mol Sci. 2015 Jun 09;16(6):13023-42
pubmed: 26068233
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
PLoS One. 2013 Jun 18;8(6):e66430
pubmed: 23824039
Free Radic Biol Med. 2000 Aug;29(3-4):222-30
pubmed: 11035250
Cancer Res. 1996 Sep 1;56(17):4006-12
pubmed: 8752171
Eur J Med Chem. 2008 Mar;43(3):668-74
pubmed: 17692434
Med Hist. 1999 Apr;43(2):192-207
pubmed: 10885139
Eur J Med Chem. 2016 Sep 14;120:51-63
pubmed: 27187858
Clin Cancer Res. 1996 Nov;2(11):1843-9
pubmed: 9816139
J Tradit Complement Med. 2014 Oct;4(4):253-7
pubmed: 25379467
Cell Death Differ. 2008 Jul;15(7):1113-23
pubmed: 18309324
Mutat Res. 2007 Oct 1;623(1-2):14-23
pubmed: 17498749
Bioorg Med Chem. 2012 Sep 15;20(18):5388-95
pubmed: 22595422
In Vivo. 2008 May-Jun;22(3):305-9
pubmed: 18610740
Expert Opin Ther Pat. 2014 Jun;24(6):647-64
pubmed: 24848259
Eur J Med Chem. 2014 Mar 3;74:491-501
pubmed: 24502897
Integr Cancer Ther. 2006 Mar;5(1):63-82
pubmed: 16484715
Eur J Med Chem. 2012 Nov;57:283-95
pubmed: 23072739
Mol Pharm. 2012 Apr 2;9(4):996-1010
pubmed: 22380484
Science. 2009 Mar 27;323(5922):1718-22
pubmed: 19325113
Sci Rep. 2018 Jan 29;8(1):1722
pubmed: 29379131
J Am Coll Nutr. 2005 Feb;24(1):16-21
pubmed: 15670980
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Free Radic Biol Med. 2018 Feb 1;115:447-457
pubmed: 29248722
Eur J Med Chem. 2010 Feb;45(2):555-63
pubmed: 19926172
J Inorg Biochem. 2016 Mar;156:64-74
pubmed: 26775277
J Pharm Pharmacol. 2016 Sep;68(9):1119-30
pubmed: 27350211
Toxicol In Vitro. 2008 Feb;22(1):232-9
pubmed: 17904330
Exp Cell Res. 2001 Oct 1;269(2):193-201
pubmed: 11570811
Eur J Pharmacol. 2014 Apr 15;729:30-6
pubmed: 24530441
Biochem Biophys Res Commun. 2018 Jan 1;495(1):368-374
pubmed: 29030066
Gastroenterology. 2008 May;134(5):1296-310
pubmed: 18471507
Eur J Pharmacol. 2006 Dec 28;553(1-3):28-38
pubmed: 17045260
Eur J Pharmacol. 2009 Jan 14;602(2-3):223-9
pubmed: 19071108
Nat Rev Cancer. 2009 Jul;9(7):501-7
pubmed: 19550425
Saudi Pharm J. 2017 Feb;25(2):206-213
pubmed: 28344470
Integr Cancer Ther. 2004 Dec;3(4):333-41
pubmed: 15523104
Drug Discov Today. 2012 Apr;17(7-8):343-51
pubmed: 22119877
Cancer Treat Rev. 2012 Aug;38(5):473-83
pubmed: 21982720
Curr Drug Targets. 2012 Jul;13(8):1006-28
pubmed: 22594470
Basic Clin Pharmacol Toxicol. 2014 Sep;115(3):244-56
pubmed: 25275147
Bioorg Med Chem Lett. 2006 Nov 1;16(21):5507-12
pubmed: 16931010
Chem Biol Drug Des. 2018 Feb;91(2):505-518
pubmed: 28944565
Pharm Biol. 2014 Oct;52(10):1351-7
pubmed: 25026344
Gynecol Oncol. 2003 Mar;88(3):434-9
pubmed: 12648599
Biomed Pharmacother. 2014 Oct;68(8):959-67
pubmed: 25458793
Cell Signal. 2008 Dec;20(12):2221-30
pubmed: 18793717
Oncology. 2001;61 Suppl 1:3-13
pubmed: 11598409
J Pharmacopuncture. 2016 Mar;19(1):51-8
pubmed: 27280050
J Mol Graph Model. 2006 Oct;25(2):169-75
pubmed: 16413803
CA Cancer J Clin. 2005 Sep-Oct;55(5):319-21
pubmed: 16166076
Bioorg Med Chem Lett. 2014 Dec 1;24(23):5413-7
pubmed: 25453799
Tumour Biol. 2017 Mar;39(3):1010428317695011
pubmed: 28351316
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Drug Discov. 2011 Dec 16;11(1):25-36
pubmed: 22173432
J Agric Food Chem. 2016 Feb 3;64(4):725-37
pubmed: 26758628
Curr Med Chem Anticancer Agents. 2001 Nov;1(3):219-35
pubmed: 12678755